CHRONIC GASTRITIS PART 2. DIAGNOSTICS. TREATMENT. PREVENTION. DISPENSARY OBSERVATION

The second part of the article describes modern approaches to the diagnosis and treatment of chronic gastritis, methods of prevention and principles of follow-up.

The progression of chronic gastritis leads to degenerative changes in the gastric mucosa – atrophy, intestinal metaplasia, dysplasia. Atrophic gastritis is a precancerous disease, therefore, choosing the right management tactics for a patient with chronic gastritis can serve as a preventive measure for gastric adenocarcinoma.

1. Ivashkin V. T., Maev I. V., Lapina T. L., Fedorov E. D., Sheptulin A. A., Truhmanov A. S., Kononov A. V., Abdulhakov R. A., Alekseeva O. P., Alekseenko S. A., Andreev D. N., Baranskaya E. K., Dekhnich N. I., Klyaritskaya I. L., Kozlov R. S., Kogan E. A., Korolev M. P., Korochanskaya N. V., Kurilovich S. A., Livzan M. A., Osipenko M. F., Pavlov P. V., Pirogov S. S., Sarsenbaeva A. S., Simanenkov V. I., Tertychnyj A. S., Tkachev A. V., Uspenskij Yu.P., Hlynov I. B., Cukanov V. V. Klinicheskie rekomendacii Rossijskoj gastroenterologicheskoj associacii i associacii «Endoskopicheskoe obshchestvo RENDO» po diagnostike i lecheniyu gastrita, duodenita. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2021;31(4):70–99. https://doi.org/10.22416/1382-4376-2021-31-4-70-99.

2. Klinicheskij protokol «Diagnostika i lechenie pacientov s zabolevaniyami organov pishchevareniya»: postanovlenie Ministerstva zdravoohraneniya Respubliki Belarus’ ot 01.06.2017 № 54.

3. Silivonchik N. N., Yakubchik T. N., Yanul A. N. Helicobacter pylori-2022 // Semejnyj doktor, Minsk, 2022 (4): 16–26.

4. Yanovich O. O. Associaciya mutacij v gene 23S rRNK Nelicobacter pylori, svyazannyh s rezistentnost’yu k klaritromicinu, s aktivnost’yu vospaleniya i morfologicheskimi izmeneniyami slizistoj obolochki zheludka / O. O. Yanovich, L. P. Titov, M. V. Doroshko // Sovremennye problemy infekcionnoj patologii cheloveka: sb. nauch. tr. / M-vo zdravoohr. Resp. Belarus’. RNPC epidemiologii i mikrobiologii; pod red. V. A. Gorbunova. – Minsk: Izd. centr BGU, 2022; Vyp. 14: 109–113.

5. Cheng H. C., Tsai Y. C., Yang H. B. et al. The corpuspredominant gastritis index can be an early and reversible marker to identify the gastric cancer risk of Helicobacter pylori-infected nonulcer dyspepsia. Helicobacter. 2017;00: e12385. https://doi.org/10.1111/hel.12385

6. Kyoto global consensus report on Helicobacter pylori gastritis / K. Sugano [et al.] // Gut. 2015; 64, (9): 1353–1367.

7. Lenti M. V., Rugge M., Lahner E., Miceli E., Toh B. H., Genta R. M., De Block C., Hershko C., Di Sabatino A. Autoimmune gastritis // Nat Rev Dis Primers. 2020; 6 (1): 56. DOI: 10.1038/s41572-020-0187-8. PMID: 32647173.

8. Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report // Gut. 2022; 71 (9): 1724–1762.

9. Mayo Tsuboi, Ryota Niikura, Yoku Hayakawa, Yoshihiro Hirata, Tetsuo Ushiku, Kazuhiko Koike1 Distinct Features of Autoimmune Gastritis in Patients with OpenType Chronic Gastritis in Japan // Biomedicines. 2020; 8 (10): 419.

10. Pennelli G., Grillo F. Galuppini F., et al. Gastritis: update on etiological features and histological practical approach // Pathologica. 2020; 112: 153-165. https://doi.org/10.32074/1591-951X-163.

11. Rugge M., Sugano K., Scarpignato C., et al. Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging // Helicobacter. 2019; 24: e12571. https://doi.org/10.1111/hel.1257148.